^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RD118

    i
    Other names: RD118, CAR-GPRC5D, Anti-GPRC5D CAR T cell therapy, CAR-T (CAR-GPRC5D), RD 118, RD-118
    Associations

    News

    Trials
    Company:
    IASO BIO
    Drug class:
    GPRC5D-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (clinicaltrials.gov)
    P1, N=12, Recruiting, Nanjing IASO Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    IL6 (Interleukin 6) • GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
    |
    GPRC5D expression
    |
    RD118
    over1year
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Nanjing IASO Biotherapeutics Co.,Ltd
    New P1 trial • CAR T-Cell Therapy
    |
    IL6 (Interleukin 6) • GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
    |
    RD118
    over2years
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, Chunrui Li | Not yet recruiting --> Recruiting | Trial completion date: Mar 2023 --> Mar 2024
    Enrollment open • Trial completion date • CAR T-Cell Therapy
    |
    IL6 (Interleukin 6) • GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
    |
    RD118
    almost3years
    A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Huazhong University of Science and Technology
    New P1 trial • CAR T-Cell Therapy
    |
    IL6 (Interleukin 6) • GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
    |
    RD118